Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01351688 | An Open Label Prostate Cancer Study in Japanese Patients | PHASE1 | COMPLETED | 13 | — | — | Aug 1, 2011 | May 1, 2013 | Jul 3, 2013 | 2 | Japan |
| NCT01162395 | Open Label Prostate Cancer Study | PHASE1 | COMPLETED | 64 | — | — | Aug 1, 2010 | Oct 1, 2015 | Jan 12, 2016 | 5 | United States, Netherlands +1 |
Number of participants with adverse events
| Arm | Type | Description |
|---|---|---|
| AZD3514 | EXPERIMENTAL | Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD) |
| A | EXPERIMENTAL | Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD) |
| Name | Type | Description |
|---|---|---|
| AZD3514 | DRUG | Patients will be given AZD3514 tablets or capsules administered orally as a single dose, and then multiple once-daily dosing following a 7 day washout. |
Inclusion Criteria: * Males aged 20 years or older. * Histologically or Cytologically proven diagnosis of prostate cancer for which no standard therapy is currently considered appropriate * Documented evidence of metastatic prostate cancer * Serum testosterone concentration ≤50 ng/dL * World Health...